embecta to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results
Embecta Corp. (Nasdaq: EMBC) announced it will host a conference call on December 20, 2022, at 8:00 a.m. ET to discuss its fiscal Q4 and full-year 2022 financial results, along with preliminary guidance for fiscal year 2023.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Embecta Corp. (Nasdaq: EMBC) announced it will host a conference call on December 20, 2022, at 8:00 a.m. ET to discuss its fiscal Q4 and full-year 2022 financial results, along with preliminary guidance for fiscal year 2023. As a leading diabetes care company, Embecta aims to leverage its nearly 100-year expertise in insulin delivery to enhance life quality for diabetes patients. The call will discuss significant operational updates, and a replay will be available post-call on their investor relations website.
Positive
- Embecta is one of the largest pure-play diabetes care companies globally.
- The company has nearly 100 years of experience in insulin delivery.
Negative
- None.
Details
News Market Reaction – EMBC
The recorded move for EMBC in the trading session of this news was +4.25%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARSIPPANY, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, will host a conference call to discuss its fiscal fourth quarter and full year 2022 financial results, and provide an operational update, including preliminary fiscal year 2023 financial guidance, at 8:00 a.m. Eastern Time (ET) on Tuesday, December 20, 2022.
Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.embecta.com.
A webcast replay of the call will be available beginning at 11:00 a.m. ET on December 20, 2022, via the embecta investor relations website and archived on the website for one year.
About embecta
embecta, formerly part of BD (Becton, Dickinson and Company), is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com.
CONTACTS
Investors:
Pravesh Khandelwal
VP, Head of Investor Relations
551-264-6547
Contact IR
Media:
Christian Glazar
Sr. Director, Corporate Communications
908-821-6922
Contact Media Relations
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.